Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of FXS6837 in primary IgA nephropathy
CTR20262849Phase 2Active
- Sponsor
- Xinghao Pengbo
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FXS6837 in IgA nephropathy (IgAN), sponsored by Xinghao Pengbo. Primary endpoint: Incidence and severity of adverse events. Started Sep 2026; status: active.
02
Drugs
FXS6837
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20262849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262849.